The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding ...

Female leaders in the Boston area’s life sciences industry talked about their leadership styles, their career paths and the ...

As obesity clinical trials evolve, there is a growing emphasis on how decentralisation and new technologies can play a role.

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Zealand Pharma CEO Adam Steensberg said Friday that the company is working on a next-generation weight loss drug that’s ...

Health-care costs are going up and and yet, workers may still not get the coverage they want — particularly when it comes to drugs like Ozempic.

Thermo Fisher Scientific is responsible for helping to produce some of the hottest drugs on the market, including Novo ...

In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), ...

Six years ago, Sanofi gave $125 million and promised over $1 billion in milestone payments to buzzy neuroscience startup ...

This summary provides a snapshot of current health news, including IPO pricing by biotech startups, Sanofi's potential sale of its consumer health business, HMI Medical's acquisition in Singapore, a ...